EVEROTAS 10MG TABLETS |

EVEROLIMUS| MHP

 Million Health Pharmaceuticals
SYNOPSIS
 DESCRIPTION
 PRESCRIBING INFORMATION
 MECHANISM OF ACTION
 EVEROTAS 10Mg
 PRODUCT DETAILS
 PHARMACOKINETICS
 DOSAGE MANAGEMENT
 PRECAUTIONS
  SIDE EFFECTS
 DRUG INTERACTION
 CONTRAINDICATIONS
 PREGNANCY
 LACTATION
 STORAGE
 MISSED DOSE
 OVERDOSAGE
 CONTACT US
DESCRIPTION:
 Everotas 10mg is a derivative of Rapamycin
(sirolimus) and works similarly to Rapamycin as an
mTOR (mammalian target of rapamycin) inhibitor. 

 Itis normally used as an immunosuppressant to

prevent rejection of organ transplants. 
In a similar fashion to other mTOR inhibitors
Everolimus' effect is solely on the mTORC1 protein
and not on the mTORC2 protein.
RENAL CARCINOMA
PRESCRIBING INFORMATION:
 Everotas
10mg tablet are mainly indicated for the
treatment of Renal carcinoma.

 Everotas
10mg  are mainly indicated for the
treatment of Breast carcinoma.

 Everotas
10mg tablet are mainly indicated for the
treatment of Brain carcinoma.

 Everotas10mg is also used in various advanced stage

cancer in stomach, intestines or pancreas.
BREAST CARCINOMA
MECHANISM OF ACTION:

 Everolimus is an mTOR prohibitor, joints at

high compatibility to FK506 binding protein
12, via producing drug complex which
inhibits the specific of mTOR.

This inhibition decreases the activity of
effectors downstream, that may cause
blockage of cell progression from G1 into S
phase, subsequently causes cell growth
arrest and apoptosis
EVEROTAS 10MG
PRODUCT DETAILS:

 Brand : Everotas 

 Ingredients : Everolimus 

 Strength : 10mg

 Manufactured : Intas pharmaceuticals Ltd 

 Package : 10 tablets
PHARMACOKINETICS
 ABSORPTION

The high plasma concentration time of Everolimus is 1 to 2 hours.

The effect of food with Everotas 10mg that with heavy meal

 DISTRIBUTION:

Everotas 10mg human plasma protein bound with the range of 74%.

 METABOLISM:

The metabolism of Everolimus is occurred in liver, which is a substrate of

CYP3A4.

 EXCRETION:

5% in urine; the parent compound has been detected in urine or feces.

DOSAGE MANAGEMENT:

 In breast cancer, renal cell cancer, pancreatic cancer,

Neuro endocrine cancer:
The prescribed dosage is 10mg should be taken as a
single dose.

 In Brain or intracranial cancer:

The prescribed dosage of Everotas 10Mg is 4.5mg/m2
orally as a single dose.

 The usual pediatric dosage of Everotas 10mg in brain or

intracranial tumor is 4.5mg/m2 should be taken orally
as a single dose.
Everotas 10mg tablet should be administered with or
without food.
PRECAUTIONS:
Lymphomas:

Increased exposure of skin cancers, patient may protect from UV light

Serious infections:

Patients receiving Everotas 10mg have high risk of acquiring various infections related to

bacteria, virus, and fungi.

 Hepatic artery thrombosis:

In liver transplant patients, Everotas 10mg therapy should not be recommended.

 Nephrotoxicity: 

Renal function should be monitored frequently; caution should be taken while using 
Everotas 10mg in renal impaired patients.
SIDE EFFECTS

• Hypersensitivity reactions
• Lymphomas & other malignancy
• Serious infections
• Kidney graft thrombosis
• Hepatic artery thrombosis
• Nephrotoxicity
• Hyperlipemia
• Angioedema
• Interstitial lung disease
• Thrombocytopenia
• Male infertility
• Proteinuria
• New commencement of diabetes .
DRUG INTERACTION:

 • Everotas10mg interaction with strong inhibitor of CYP3A4, or

P-gp, leads to cause decreasing the efflux of Everolimus and
increase the plasma concentration of Everolimus.
• Combination of Everotas 10mg with verapamil leads to
increasing the plasma concentration of Everolimus.
• Combination of Everotas 10mg with Atorvastatin or pravastatin
causes rhabdomyolysis, due to increasing concentration of lipid
lowering agents.
• Everotas 10mg combination with strong CYP3A4 inducers,
causes increasing the exposure of Everolimus.
• Concomitant use of Everotas 10mg with cyclosporine causes
increasing the AUC level of Everolimus frequently.
• Everotas 10mg tablet is interaction with ketoconazole or other
CYP3A4 inhibitors causes increasing the plasma concentration
and AUC of Everolimus.
• Concomitant use with erythromycin causes increasing in AUC of
Everolimus.
CONTRAINDICATIONS

 Some anaphylactic reaction occurs, if

patients are contraindicated to the
components present in the Everotas
10mg tablet.
PREGNANCY:

 Pregnancy category C Everotas 10mg is

needed only by the patients after knowing
the benefits to the mother outweighs the risk
to fetus.
STORAGE :

 Everotas 10mg tablet should be kept at 25°C

Keep the tablet away from moisture, heat
and light
Dispense only in original container.
MISSED DOSE

 If patient failed to take a single dose,

patients must consult with medical
practitioner and follow the instructions given
by them. Or the missed dose should be
avoiding and follow the regular dosing
schedule.
OVERDOSAGE

 The over dosage of Everolimus is rarely

occur, in case of over dosage patient must be
provide with supportive measures. The acute
toxicity of Everolimus over dosage should be
monitored.
CONTACT US

 PHONE NO: +91-9940472902

 EMAIL: millionhealthpharmaceuticals@gmail.com

 WEBSITEURL:https
://millionpharma.com/everotas-10-mg.php